Newsfeeds - Spark Newswire

3 minute read

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton’s Partnered Epilepsy Drug, ASCO Conference Gets Underway And More

Today, 6:49 PM

Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for the year-to-date period.

ABBV

1 minute read

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane

By Vandana Singh

Today, 6:49 PM

Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have

BIIB

2 minute read

The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More

By Shanthi Rexaline

Today, 6:49 PM

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that encompassed the JPM Healthcare conference.

ABT

1 minute read

UCB’s Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study

By Vandana Singh

Today, 6:49 PM

UCB SA (OTC: UCBJF)

UCBJF

4 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For September 2, 2021

By Benzinga Insights

Today, 6:49 PM

ALKS

1 minute read

JP Morgan Upgrades UCB to Overweight

By Benzinga Newsdesk

Today, 6:49 PM

JP Morgan analyst Richard Vosser upgrades UCB (OTC:UCBJY) from Neutral to Overweight.

UCBJY

1 minute read

UCB Gets EU Approval For Bimekizumab In Psoriasis

By Vandana Singh

Today, 6:49 PM

The European Commission has cleared UCB’s (OTC:UCBJF) Bimzelx (bimekizumab) for moderate to severe plaque psoriasis in adults. UCB’s confidence lies in…

NVS

4 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For August 23, 2021

By Benzinga Insights

Today, 6:49 PM

Upgrades JP Morgan upgraded the previous rating for Pearson PLC (NYSE:PSO) from Neutral to Overweight. The current stock performance of Pearson shows a 52-week-high of $12.38 and a 52-week-low of $6.13. Moreover, at the end of the last trading period, the closing price was at $10.41.

ACVA